Clinical Utility of a Unique Genome-Wide DNA Methylation Signature for KMT2A-Related Syndrome - Archive ouverte HAL Access content directly
Journal Articles International Journal of Molecular Sciences Year : 2022

Clinical Utility of a Unique Genome-Wide DNA Methylation Signature for KMT2A-Related Syndrome

(1, 2) , (1, 2) , (2) , (2) , (2) , (2) , (3) , (3) , (3) , (3) , (4) , (5) , (6, 7) , (8, 9) , (10, 11) , (12) , (13) , (14) , (15) , (16) , (17) , (18, 19) , (18, 19) , (20) , (21) , (22) , (23) , (24) , (3) , (1, 2) , (25, 26)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
Pratibha Bhai
Michael A Levy
  • Function : Author
  • PersonId : 1125501
Jennifer Kerkhof
Haley Mcconkey
Lucia Pedace
  • Function : Author
  • PersonId : 1125502
Solveig Heide
  • Function : Author
  • PersonId : 1012475
Eric Bieth
  • Function : Author
  • PersonId : 948825
Silvia Maitz

Abstract

Wiedemann–Steiner syndrome (WDSTS) is a Mendelian syndromic intellectual disability (ID) condition associated with hypertrichosis cubiti, short stature, and characteristic facies caused by pathogenic variants in the KMT2A gene. Clinical features can be inconclusive in mild and unusual WDSTS presentations with variable ID (mild to severe), facies (typical or not) and other associated malformations (bone, cerebral, renal, cardiac and ophthalmological anomalies). Interpretation and classification of rare KMT2A variants can be challenging. A genome-wide DNA methylation episignature for KMT2A-related syndrome could allow functional classification of variants and provide insights into the pathophysiology of WDSTS. Therefore, we assessed genome-wide DNA methylation profiles in a cohort of 60 patients with clinical diagnosis for WDSTS or Kabuki and identified a unique highly sensitive and specific DNA methylation episignature as a molecular biomarker of WDSTS. WDSTS episignature enabled classification of variants of uncertain significance in the KMT2A gene as well as confirmation of diagnosis in patients with clinical presentation of WDSTS without known genetic variants. The changes in the methylation profile resulting from KMT2A mutations involve global reduction in methylation in various genes, including homeobox gene promoters. These findings provide novel insights into the molecular etiology of WDSTS and explain the broad phenotypic spectrum of the disease.
Fichier principal
Vignette du fichier
Foroutan et al. Int. J. Mol. Sci. 2022.pdf (1.92 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

inserm-03561254 , version 1 (08-02-2022)

Identifiers

Cite

Aidin Foroutan, Sadegheh Haghshenas, Pratibha Bhai, Michael A Levy, Jennifer Kerkhof, et al.. Clinical Utility of a Unique Genome-Wide DNA Methylation Signature for KMT2A-Related Syndrome. International Journal of Molecular Sciences, 2022, 23 (3), pp.1815. ⟨10.3390/ijms23031815⟩. ⟨inserm-03561254⟩
48 View
40 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More